The 2023 Pipeline of Disease-Modifying Antirheumatic Drugs (DMARDs) in Clinical Development for Spondyloarthritis (including psoriatic arthritis): a Systematic Review of Trials
RMD Open. 2023;9(3):e003279 doi 10.1136/rmdopen-2023-003279 https://pubmed.ncbi.nlm.nih.gov/37507210/
This systematic review identified DMARDs evaluated for axSpA and PsA, distinguishing between csDMARDs, tsDMARDs, and bDMARDs. The review pinpointed twenty-six distinct targeted therapies currently in clinical development; 18 therapies for axSpA and 15 therapies for PsA.
Trials retrieved from databases (N=3574) filtered through research terms to identify DMARDs developed for spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis; 9 csDMARDs (5 withdrawn, 1 in development, and 3 marketed), 37 bDMARDs (10 withdrawn, 16 in development, and 11 marketed) and 17 tsDMARDs (5 withdrawn, 9 in development, and 3 marketed) were identified.
The review demonstrated an unmet need in developing strategies or biomarkers to aid clinicians in making informed treatment decisions.
Keywords:
